Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. is set to present promising results from their Phase 2b SPRINGBOARD study at the OARSI World Congress 2024, offering new hope for knee osteoarthritis patients with their drug EP-104IAR. The study reports meaningful improvements in pain and a favorable safety profile, indicating EP-104IAR as a transformative treatment for managing cartilage health. The company’s patented Diffusphere™ technology underpins their commitment to developing long-lasting, targeted therapies for conditions with high unmet medical needs.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
